Efficacy

Orserdu (Elacestrant) Efficacy in Breast Cancer

Orserdu, with the active ingredient elacestrant, is a novel oral selective estrogen receptor degrader (SERD) that has shown efficacy in the treatment of estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Clinical trials have demonstrated that Orserdu is effective in patients who have previously received endocrine therapy and CDK4/6 inhibitors. In these studies, Orserdu has shown a statistically significant improvement in progression-free survival compared to standard endocrine therapies. This suggests that Orserdu can be a promising treatment option for patients with ER+ HER2- breast cancer, particularly after other therapies have failed.

Furthermore, the efficacy of Orserdu has been observed in both premenopausal and postmenopausal women, indicating its broad potential in the breast cancer patient population. The drug's mechanism of action involves degrading the estrogen receptor, thereby inhibiting the proliferative signaling pathways that drive the growth of ER+ breast cancer cells. This targeted approach is critical in managing breast cancer subtypes that are reliant on estrogen for tumor growth.

Truqap (Capivasertib) Efficacy in Breast Cancer

Truqap, known by its generic name capivasertib, is an investigational AKT inhibitor that has shown promise in the treatment of breast cancer. Capivasertib targets the AKT signaling pathway, which is often dysregulated in cancers, including breast cancer. In clinical studies, Truqap has been evaluated in combination with other therapies, such as fulvestrant, for the treatment of hormone receptor-positive, HER2-negative advanced breast cancer. The results from these studies indicate that capivasertib, when added to standard endocrine therapy, may improve outcomes by inhibiting the growth of cancer cells and potentially overcoming resistance to endocrine therapy.

The efficacy of Truqap is particularly notable in patients with breast cancers that harbor alterations in the PIK3CA/AKT/PTEN pathway, which is a common aberration in breast cancer that can lead to resistance to endocrine therapy. By specifically inhibiting AKT, Truqap has the potential to provide a new therapeutic option for patients with this subtype of breast cancer. Ongoing clinical trials continue to assess the efficacy and safety profile of Truqap in a broader patient population to further establish its role in the management of breast cancer.